ClinicalTrials.gov
public full text
Public Domain
A Study of LY3537021 in Healthy Participants
The main purpose of this study is to evaluate the safety and tolerability of LY3537021 when administered in combination with glucagon-like peptide (GLP-1) receptor agonist called liraglutide in treatment-naïve healthy participants. The study will include 2 parts. The study will last up to 16 and 22 weeks for part A and B, respectively which includes a screening period of 6 weeks.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of LY3337641 in Japanese and Caucasian Healthy Participants#1339892
- A Study of LY3463251 in Healthy Participants#906560
- A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus#868322
- A Study of LY3143753 and LY3185643 in Healthy Participants#1162461
- A Safety Study of LY3372689 in Healthy Participants#1172415
Record · ID 1338582
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive